Neuroblastoma signalling models unveil combination therapies targeting feedback-mediated resistance.

Very high risk neuroblastoma is characterised by increased MAPK signalling, and targeting MAPK signalling is a promising therapeutic strategy. We used a deeply characterised panel of neuroblastoma cell lines and found that the sensitivity to MEK inhibitors varied drastically between these cell lines...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mathurin Dorel, Bertram Klinger, Tommaso Mari, Joern Toedling, Eric Blanc, Clemens Messerschmidt, Michal Nadler-Holly, Matthias Ziehm, Anja Sieber, Falk Hertwig, Dieter Beule, Angelika Eggert, Johannes H Schulte, Matthias Selbach, Nils Blüthgen
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/6c6e8d855b1e45b79a37ebbd2f6a6b10
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6c6e8d855b1e45b79a37ebbd2f6a6b10
record_format	dspace
spelling	oai:doaj.org-article:6c6e8d855b1e45b79a37ebbd2f6a6b102021-12-02T19:57:59ZNeuroblastoma signalling models unveil combination therapies targeting feedback-mediated resistance.1553-734X1553-735810.1371/journal.pcbi.1009515https://doaj.org/article/6c6e8d855b1e45b79a37ebbd2f6a6b102021-11-01T00:00:00Zhttps://doi.org/10.1371/journal.pcbi.1009515https://doaj.org/toc/1553-734Xhttps://doaj.org/toc/1553-7358Very high risk neuroblastoma is characterised by increased MAPK signalling, and targeting MAPK signalling is a promising therapeutic strategy. We used a deeply characterised panel of neuroblastoma cell lines and found that the sensitivity to MEK inhibitors varied drastically between these cell lines. By generating quantitative perturbation data and mathematical modelling, we determined potential resistance mechanisms. We found that negative feedbacks within MAPK signalling and via the IGF receptor mediate re-activation of MAPK signalling upon treatment in resistant cell lines. By using cell-line specific models, we predict that combinations of MEK inhibitors with RAF or IGFR inhibitors can overcome resistance, and tested these predictions experimentally. In addition, phospho-proteomic profiling confirmed the cell-specific feedback effects and synergy of MEK and IGFR targeted treatment. Our study shows that a quantitative understanding of signalling and feedback mechanisms facilitated by models can help to develop and optimise therapeutic strategies. Our findings should be considered for the planning of future clinical trials introducing MEKi in the treatment of neuroblastoma.Mathurin DorelBertram KlingerTommaso MariJoern ToedlingEric BlancClemens MesserschmidtMichal Nadler-HollyMatthias ZiehmAnja SieberFalk HertwigDieter BeuleAngelika EggertJohannes H SchulteMatthias SelbachNils BlüthgenPublic Library of Science (PLoS)articleBiology (General)QH301-705.5ENPLoS Computational Biology, Vol 17, Iss 11, p e1009515 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Biology (General) QH301-705.5
spellingShingle	Biology (General) QH301-705.5 Mathurin Dorel Bertram Klinger Tommaso Mari Joern Toedling Eric Blanc Clemens Messerschmidt Michal Nadler-Holly Matthias Ziehm Anja Sieber Falk Hertwig Dieter Beule Angelika Eggert Johannes H Schulte Matthias Selbach Nils Blüthgen Neuroblastoma signalling models unveil combination therapies targeting feedback-mediated resistance.
description	Very high risk neuroblastoma is characterised by increased MAPK signalling, and targeting MAPK signalling is a promising therapeutic strategy. We used a deeply characterised panel of neuroblastoma cell lines and found that the sensitivity to MEK inhibitors varied drastically between these cell lines. By generating quantitative perturbation data and mathematical modelling, we determined potential resistance mechanisms. We found that negative feedbacks within MAPK signalling and via the IGF receptor mediate re-activation of MAPK signalling upon treatment in resistant cell lines. By using cell-line specific models, we predict that combinations of MEK inhibitors with RAF or IGFR inhibitors can overcome resistance, and tested these predictions experimentally. In addition, phospho-proteomic profiling confirmed the cell-specific feedback effects and synergy of MEK and IGFR targeted treatment. Our study shows that a quantitative understanding of signalling and feedback mechanisms facilitated by models can help to develop and optimise therapeutic strategies. Our findings should be considered for the planning of future clinical trials introducing MEKi in the treatment of neuroblastoma.
format	article
author	Mathurin Dorel Bertram Klinger Tommaso Mari Joern Toedling Eric Blanc Clemens Messerschmidt Michal Nadler-Holly Matthias Ziehm Anja Sieber Falk Hertwig Dieter Beule Angelika Eggert Johannes H Schulte Matthias Selbach Nils Blüthgen
author_facet	Mathurin Dorel Bertram Klinger Tommaso Mari Joern Toedling Eric Blanc Clemens Messerschmidt Michal Nadler-Holly Matthias Ziehm Anja Sieber Falk Hertwig Dieter Beule Angelika Eggert Johannes H Schulte Matthias Selbach Nils Blüthgen
author_sort	Mathurin Dorel
title	Neuroblastoma signalling models unveil combination therapies targeting feedback-mediated resistance.
title_short	Neuroblastoma signalling models unveil combination therapies targeting feedback-mediated resistance.
title_full	Neuroblastoma signalling models unveil combination therapies targeting feedback-mediated resistance.
title_fullStr	Neuroblastoma signalling models unveil combination therapies targeting feedback-mediated resistance.
title_full_unstemmed	Neuroblastoma signalling models unveil combination therapies targeting feedback-mediated resistance.
title_sort	neuroblastoma signalling models unveil combination therapies targeting feedback-mediated resistance.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/6c6e8d855b1e45b79a37ebbd2f6a6b10
work_keys_str_mv	AT mathurindorel neuroblastomasignallingmodelsunveilcombinationtherapiestargetingfeedbackmediatedresistance AT bertramklinger neuroblastomasignallingmodelsunveilcombinationtherapiestargetingfeedbackmediatedresistance AT tommasomari neuroblastomasignallingmodelsunveilcombinationtherapiestargetingfeedbackmediatedresistance AT joerntoedling neuroblastomasignallingmodelsunveilcombinationtherapiestargetingfeedbackmediatedresistance AT ericblanc neuroblastomasignallingmodelsunveilcombinationtherapiestargetingfeedbackmediatedresistance AT clemensmesserschmidt neuroblastomasignallingmodelsunveilcombinationtherapiestargetingfeedbackmediatedresistance AT michalnadlerholly neuroblastomasignallingmodelsunveilcombinationtherapiestargetingfeedbackmediatedresistance AT matthiasziehm neuroblastomasignallingmodelsunveilcombinationtherapiestargetingfeedbackmediatedresistance AT anjasieber neuroblastomasignallingmodelsunveilcombinationtherapiestargetingfeedbackmediatedresistance AT falkhertwig neuroblastomasignallingmodelsunveilcombinationtherapiestargetingfeedbackmediatedresistance AT dieterbeule neuroblastomasignallingmodelsunveilcombinationtherapiestargetingfeedbackmediatedresistance AT angelikaeggert neuroblastomasignallingmodelsunveilcombinationtherapiestargetingfeedbackmediatedresistance AT johanneshschulte neuroblastomasignallingmodelsunveilcombinationtherapiestargetingfeedbackmediatedresistance AT matthiasselbach neuroblastomasignallingmodelsunveilcombinationtherapiestargetingfeedbackmediatedresistance AT nilsbluthgen neuroblastomasignallingmodelsunveilcombinationtherapiestargetingfeedbackmediatedresistance
_version_	1718375781764169728

Neuroblastoma signalling models unveil combination therapies targeting feedback-mediated resistance.

Ejemplares similares